Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash from Investing Activities for 18 years, with the latest figure at -$92.7 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 91.53% year-over-year to -$92.7 million in Q2 2026; TTM through Jun 2026 was -$704.2 million, a 5.06% decrease from a year earlier, with the FY2025 full-year figure at -$629.1 million, up 74.51% from the prior year.
• Cash from Investing Activities was -$92.7 million for Q2 2026 at Regeneron Pharmaceuticals, up from -$428.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $647.5 million in Q1 2025, with the low at -$2.4 billion in Q2 2023.
• Average Cash from Investing Activities over 5 years is -$588.2 million, with a median of -$421.4 million recorded in 2022.
• The largest YoY upside for Cash from Investing Activities was 629.61% in 2024 against a maximum downside of 615.78% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$1.9 billion in 2022, then soared by 96.44% to -$66.2 million in 2023, then surged by 629.61% to $350.6 million in 2024, then tumbled by 37.16% to $220.3 million in 2025, then sank by 142.08% to -$92.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$92.7 million (Q2 2026), -$428.9 million (Q1 2026), and $220.3 million (Q4 2025), per Business Quant data.